Cancer research in India has risen in size and influence during the last 20 years. From low-tech, large-scale health outcomes to some of the most sophisticated fields of fundamental cancer science, Indian clinicians, scientists, and federal and state policymakers have championed cancer research. Cancer research in India is a complicated setting in which public policy must be balanced across numerous conflicting goals. During method development, carry-over should be handled and minimized. Carry-over should be tested during validation by injecting blank samples after a high concentration sample or calibration standard at the quantification's upper limit. Carry over in the blank sample after the high concentration standard should not exceed 20% of the lower limit of quantification, and 5% for the internal standard. If carry-over looks to be unavoidable, the study samples should not be randomized. Specific procedures should be considered, evaluated during validation, and implemented during the analysis of study samples to ensure that accuracy and precision are not compromised.